Nuttall Women’s Health has launched research funding and investment programs targeting female-specific biology and women’s health companies. The organization offers grants ranging from $500,000 to $5 million per research project and invests in early to growth stage companies.
The research funding operates through Request for Proposals addressing specific areas including endometriosis biology, ovarian aging, hormones and brain health, musculoskeletal health, the gut microbiome, gynecological cancers, and female-specific biology mechanisms. Current RFPs include XXcelerate, Odessa, D³, and Franklin Factor, with MiNERVA coming soon. Projects can span one to three years, and the organization expects to fund multiple projects per RFP.
The application process includes a one-page Letter of Intent (550 words maximum), followed by a six-page expanded proposal for selected applicants, a site visit from the NWH team, and funding awards. The review process is shorter than traditional granting institutions to accelerate research timelines.
For investment funding, Nuttall Women’s Health targets companies developing devices, diagnostics, and therapeutics based on validated science with clear clinical pathways. The organization focuses on companies committed to biomarker-based approaches or mechanism-driven innovation tailored to female biology. All investment returns are reinvested into research funding opportunities.
Nuttall Women’s Health is led by CEO Michal Elovitz, MD, with founders Amie Rath Nuttall and Scott Nuttall.
